Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Owens, Amelia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S302000, C549S305000
Reexamination Certificate
active
10889029
ABSTRACT:
This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the acute malignant haemopathies.
REFERENCES:
patent: WO 00/50414 (2000-08-01), None
patent: WO 01/68070 (2001-09-01), None
Baker Botts, In Print, Reach Through Claims Apr. 12, 2002.
Lendaris, S Reach Through Crisis: Bust or Boon? Intellectual Property Update 4(5) (2004).
Barbui et al, Review Article, The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia, Blood, 91(9), May 1, 1998, 3093-3102.
Avvisati, Aida (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto (GIMMEMA) pilot study, PMID: 8695858 (1996).
Fenaux, Treatment of acute promelocytic leukaemia, PMID: 8730553 (1996).
Patent Abstracts of Japan, vol. 1998, No. 05, Apr. 30, 1998 & JP 10-007557 A (Banyu Pharmaceut Co., Ltd.) Jan. 13, 1998.
Database WPI, Section Ch, Week 199601, Derwent Publications Ltd., London GB; Class B02, AN 1996-006892, XP002223650 & JP 07 285862 A (KOKKA IY AKU KANRIKYOKU SHIKAWA KOKINSO) Oct. 31, 1995.
Visant et al.; “All-Trans Retinoic Acid Potentiates Megakaryocyte Colony Formation: In Vitro and In Vivo Effects after Administration to Acute Promyelocytic Leukemia Patient,” Leukemia, Macmillan Press Ltd., vol. 8, No. 12, Dec. 1994, pp. 2183-2187.
Yasuhiro et al., Database Biosis ′Online?, Biosciences Information Service, “Inhibition of Growth and Induction of Apoptosis by All-Trans Retinoic Acid in Lymphoid Cell Lines Transfected with the PML/RAR-Alpha Fusion Gene”, Database Accession No. PREV199699105088 XP002223648.
Findley et al., “Effect of Retinoic-Acid on the Clonal Growth of Childhood Myeloid and Lymphoid Leukemias a Pediatric Oncology Group Study”, Database Biosis ′Online?, Biosciences Information Service, Philadelphia, PA, 1984, Database Accession No. PREV198579069170 XP002223649.
Shappell et al., I5S-Hydroxyeicosatetranenoic Acid Activates Peroxisome Proliferator-Activated Receptor Gamma and Inhibits Proliferation in PC3 Prostate Carsinoma Cells:, Cancer Research, vol. 61, No. 2, Jan. 15, 2001, pp. 497-503.
Nanjoo et al., “A New Ligand For the Peroxisome Proliferator-Activated Inhibits Rat Mammary Carinogenesis”, Cancer Rearch, vol. 59, No. 22, Nov. 15, 1999, pp. 5671-5673.
Pisano Claudio
Riccioni Teresa
Nixon & Vanderhye P.C.
Owens Amelia
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Compositions useful for the treatment of pathologies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions useful for the treatment of pathologies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions useful for the treatment of pathologies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3882270